AASLD 2012: Daclatasvir + Asunaprevir + BMS-791325 Cures Hard-to-treat Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Thursday, 15 November 2012 00:00
- Written by Keith Alcorn
Twelve weeks of treatment with a 3-drug combination of new hepatitis C direct-acting antivirals that included neither pegylated interferon nor ribavirin led to sustained virological response 12 weeks after completion of treatment (SVR12) in up to 94% of previously untreated patients with hepatitis C genotype 1 in a preliminary Phase 2 trial with 16 patients, Gregory Everson from the University of Colorado reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
AASLD 2012: Tenofovir Safe and Effective for Long-term Hepatitis B Treatment with Little Bone Loss
- Details
- Category: HBV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
Tenofovir (Viread) continues to be safe and highly effective for treating chronic hepatitis B through 8 years of follow-up, researchers reported at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) this week in Boston. Another study showed minimal bone loss among tenofovir-treated patients using the FRAX method. 
AASLD 2012: Abbott Interferon-free Combination 'Promising' in Harder-to-treat People with Hep C
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 13 November 2012 00:00
- Written by Keith Alcorn
Over 79% of previously untreated and null-responder patients with genotype 1a hepatitis C achieved a sustained virological response 12 weeks after completing treatment with an interferon-free combination of 2 or 3 direct-acting antiviral agents developed by Abbott (ABT-450, ABT-267, and/or ABT-333), investigators reported at the American Association for the Stu
dy of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
AASLD 2012: Reducing Ribavirin, Adding EPO Both Manage Anemia in Hep C Patients on Boceprevir
- Details
- Category: HCV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
Chronic hepatitis C patients being treated with boceprevir (Victrelis) plus pegylated interferon and ribavirin can effectively manage drug-induced anemia, either by ribavirin dose reduction or addition of erythropoietin (EPO), without compromising treatment effectiveness, according to a presentation at theAmerican Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
Coverage of the 2012 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
HIVandHepatitis.com AASLD 2012 conference section
11/13/12
More Articles...
- AASLD 2012: Final Study Results Show Telaprevir Is Safe and Effective for HIV/HCV Coinfected Patients
- Liver Meeting Highlights: New Hep C Drugs, NAFLD, Liver Cancer, Acetaminophen Toxicity, Benefits of Coffee
- AASLD 2012: High Rate of Response to Daclatasvir and Asunaprevir in Harder-to-treat Hep C Patients
- AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis
Web Design and Development by